Downbeat retail sales data and Treasury Secretary Scott Bessent's comments are adding to worries about the economy.

U.S. retail sales rebounded marginally in February as consumers pulled back on discretionary spending, reinforcing the ...

The S&P 500 (^GSPC) has entered correction, falling 10% from its February all-time highs as political uncertainty has driven ...

Ulta Beauty (NASDAQ:ULTA – Get Free Report) had its price target lowered by BMO Capital Markets from $467.00 to $404.00 in a ...

Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a ...

BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of ...

On Thursday, BMO Capital Markets sustained their Market Perform rating on Casey’s General Stores (NASDAQ:CASY), with a steady price target of $450.00. The convenience store chain, currently ...

Stock market corrections of 10% hurt. But research shows that they often don't portend worse things ahead for stocks.

ECN Capital Corp. (TSX: ECN) ("ECN Capital” or the "Company”) today announced that it has entered into an agreement with a syndicate of underwriters (the "Underwriters”) led by CIBC Capital Markets, ...

BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of $12 ...

The revised estimates put Wall Street's average year-end target for the S&P 500 at 6,607, implying an advance of more than 17% from Friday's close of 5,638.94, according to a recent survey of Wall ...

On Tuesday, BMO Capital Markets began coverage of Avidity Biosciences (NASDAQ:RNA) shares, assigning an Outperform rating and setting a price target of $72.00. Currently trading at $29.58, the stock ...